The glucagon receptor family comprises Class B G protein-coupled receptors (GPCRs) that 17 play a crucial role in regulating blood sugar levels. Receptors of this family represent important 18 therapeutic targets for the treatment of diabetes and obesity.
residues that are present in glucagon and have been shown to be important determinants of 44 efficacy 11 . Structures of other Class B receptor:G protein complexes have shown, unlike in 45
Class A receptor complexes, the formation of a complete break in the TM6 helix that 46 accommodates the a5 helix of Gas [12] [13] [14] [15] [16] . Since the partial agonist-bound GCGR structure was 47 solved in the absence of G protein, the fully active conformation of the receptor with a 48 "kinked" TM6 was not captured. 49 In order to determine the structure of the GCGR signaling complex, we engineered a 50 glucagon analogue (ZP3780), that shows significantly improved solubility and stability in 51 aqueous solutions in comparison to the native glucagon peptide that is prone to rapidly form 52 fibrillar aggregates at neutral pH (Suppl. Fig. 1 , Suppl. Table 1 , 2) 17 . Taking advantage of our 53 previous efforts in designing glucagon analogues 18 , ZP3780 was engineered to act as a full 54 agonist by retaining the native sequence in the N-terminus of the peptide, important for ligand 55 efficiency 19 , while improving solubility and stability by iteratively substituting amino acids in 56 the C-terminus to change the peptide isoelectric point (pI) (Suppl. Fig. 1 ). The resulting 57 glucagon analogue ZP3780 includes four C-terminal mutations that only slightly reduce the 58 affinity in comparison to the wild-type glucagon (Suppl. Fig. 1 ). Activation of the receptor 59 with ZP3780 enabled the formation of a GCGR:Gs complex that was stable enough for cryo-60 electron microscopy (cryo-EM) imaging yielding a final density map at a nominal resolution 61 of 3.1Å (Fig. 1a, Suppl. Fig. 2 ). 62 peptide ligand-free state of GCGR (Fab-bound GCGR, blue, PDB 5XEZ), partial agonist 67 NNC1702-bound GCGR (orange, PDB 5YQZ), and active, full-agonist ZP3780-bound state of 68 GCGR (cyan). Significant structural change is observed in TM6, which moves outward by 18 69 Å and partially unwinds to form a kink with an angle of 105°. Additional changes are also 70 observed in TMs 1, 3, 5, and 7. 71
The cryo-EM map shows well-defined density that allowed unambiguous modeling of 72 the secondary structure and side chain orientations of all components of the GCGR-Gs 73 complex, including the full agonist peptide ZP3780 (Suppl. Fig. 2, 3, 4a ). In the structure, 74
ZP3780 forms a continuous a-helix that is bound between the extracellular domain (ECD) and 75 the transmembrane bundle of the receptor (Fig. 1a , Suppl. Fig. 4a, b ). The peptide engages 76 GCGR through extensive van der Waals and hydrophobic interactions with residues in the ECD 77 and mostly polar contacts with residues in the transmembrane domain ( Fig. 2a , Suppl. Fig. 4b-78 d). The overall peptide binding mode and the relative orientation of the ECD with respect of 79 the transmembrane domain is very similar to the recently reported crystal structure of GCGR 80
bound to the partial agonist peptide NNC1702 (Suppl. Fig. 4b ) 10 . However, significant 81 structural rearrangements are observed in the transmembrane region of the receptor ( Fig. 1b-82 d). A comparison of the previously determined full-length GCGR structures in the inactive 83 peptide-free (apo) state 9 and bound to the partial agonist NNC1702 10 with the fully active 84 ZP3780-bound complex shows that peptide binding induces not only conformational changes 85 of the ECD and the stalk region, but also at the extracellular ends of TMs 1, 2, 6, and 7 ( Fig.  86 1b, c). These rearrangements in the transmembrane region widen the ligand binding site 87
allowing the penetration of the peptide N-terminus deep into the receptor core. The GCGR:Gs 88 complex structure also reveals structural changes that are related to full activation of the 89 receptor. These include movement of the extracellular half of TM7 that bends further towards 90 TM6 (6.5 Å Ca-Ca distance between L377 7.34 ) (receptor residues in superscript are defined 91 using the class B numbering system) 20 , facilitated by the conserved G393 7.50 in the center of 92 the transmembrane domain ( Fig. 1b, c) . Furthermore, the entire TM3 shifts up by half a helix 93 turn and its extracellular end moves away from the receptor core. On the intracellular side, 94 TM5 moves towards TM6 by 6.5 Å, followed by the C-terminal end of TM3 ( Fig. 1c,d ). The 95 most profound structural rearrangement between the NNC1702-bound structure of GCGR and 96 the fully active receptor conformation in the G protein complex involves the formation of a 97
sharp kink in the middle of TM6 (105.5°, measured between V368-G359-K344) ( Fig. 1b ). As 98 reported for the previously determined active structures of other Class B GPCRs (GLP-1, CTR, 99 CGRP, and PTH), the kink pivots the intracellular half of TM6 to move outwards by 100 approximately 18Å, while the a-helical structure of the extracellular half partially unwinds 12-101 16 . The conformational differences between the NNC1702 and the ZP3780-bound structures 102 are most likely due to the distinct efficacy profiles of both ligands that are a result of sequence 103 variations in the N-terminal part of the peptides, [as well as the presence of Gs]. In the native 104 glucagon peptide, the N-terminal residues, histidine 1 (H1) and aspartate 9 (D9) have been 105
shown to be critical positions for glucagon activity 11, 21 . While those residues are present in 106 ZP3780, NNC1702 exhibits a deletion of H1 and substitution of D9 by glutamate (D9E). 107
Substitution of H1 or D9 to alanine in glucagon results in a marked reduction in ligand 108 efficacy 22 . Therefore, a comparison between the interaction patterns of the N-termini of the 109 peptides ZP3780 and NNC1702, and the transmembrane bundle (TMs 3, 5, 6, 7, and ECL3) of 110 the receptor can provide a structural framework to explain the molecular basis of ligand 111 efficacy for the glucagon receptor. 112 required for full ligand efficacy and penetrates deep in the receptor core to make hydrogen-115 bonds (H-bonds) (dotted lines) with residues in TMS 1, 3, 7 and ECL3 (cyan). b, The difference 116 in receptor recognition by full-agonist ZP3780 (red) and partial-agonist NNC1702 (blue) that 117 lacks H1 and has a D9E mutation is shown. NNC1702-bound GCGR is shown in orange (PDB 118 5YQZ) and the ZP3780-bound GCGR:Gs complex structure is shown in cyan. The polar 119
interactions are shown as dotted lines colored based on the GCGR structures bound to the two 120 ligands, respectively (ZP3780: cyan and NNC1702: orange). c, Mutation of Q232 3.37 , 121 D370 ECL3 , R378 7.35 , and D385 7.42 to alanine have a large effect on GCGR-mediated cAMP 122 signaling. All mutants were expressed to similar levels as the WT receptor. d, Comparison of 123 the interactions formed between the N-terminus of ZP3780 (red) and GCGR (cyan) and those 124 formed by NNC1702 (blue) bound to GCGR (orange, PDB 5YQZ). The presence of H1 in 125 ZP3780 ensures interaction with Q232 3.37 and rearrangement of residues in TM5. The 126
interaction of D9 stabilizes TM7 and ECL3 displacement, which might trigger GCGR 127 activation. For c, data represent mean ± s.e.m. from at least three independent experiments, 128 performed in triplicates. 129 130
In the full agonist ZP3780, the carboxyl group of D9 forms a salt bridge with residue 131 R378 7.35 on the N-terminus of TM7 that draws TM7 towards TM6 ( Fig. 2a, b ). This polar 132
interaction is also present in previously determined GLP-1:Gs complex structures and in fact 133 alanine mutation of R378 7.35 completely inhibits GCGR-mediated cAMP signaling ( Fig.  134 2c) 12,13,23 , thus highlighting the importance of this interaction for ligand-dependent activation 135 within receptors of the glucagon family. The altered position of TM7 is accompanied by 136 movement of ECL3 towards the receptor core wherein an hydrogen bond (H-bond) is formed 137 between D370 ECL3 and T5 of ZP3780 ( Fig. 2b, d ). This interaction is part of a polar network 138 that includes R378 7.35 and D9 and that stabilizes the active TM7 conformation together with 139 the H-bond between S2 and D385 7.42 . Mutation of D370 ECL3 and D385 7.42 to alanine reduces 140 ligand potency by at least 700-fold ( Fig. 2c ). The N-terminal residue H1 of ZP3780 forms a H-141 bond with residue Q232 3.37 in TM3 on the other side of the ligand binding pocket. Formation 142 of this interaction anchors the peptide deep into the ligand binding pocket and constrains its 143 movement. Alanine substitution of Q232 3.37 reduces the potency 350-fold, suggesting the 144 importance of this interaction for ligand binding and/or receptor activation. Upon peptide 145 binding, W304 5.36 in TM5 flips towards the receptor core to stabilize the H1-Q232 3.37 146 interaction by forming a "cap" that provides a further steric hindrance to peptide movement 147 within the binding pocket (Fig. 2d ). The functional importance of W304 5.36 is shown by a 148 mutation to glutamine that completely abolishes peptide binding 24 . Another consequence of the 149 inward movement of W304 5.36 seems to be to transmit the rotation through the helix to 150 facilitate a large-scale translation of the cytoplasmic side of TM5 towards TM6 upon GCGR 151
activation. 152
Comparison of the N-terminal positions of the full agonist ZP3780 and the partial 153 agonist NNC1702 shows that the absence of H1 results in an upward shift of NNC1702 towards 154 TM7 ( Fig. 2b ). In this position, the partial agonist would clash with TMs 1 and 7 in the fully 155 activated receptor (Suppl. Fig. 5 ). In addition to this steric restriction of TM1 and TM7 156 movement, the D9E mutation allows the partial agonist to form a stronger contact with the 157 extracellular end of TM7 (residues R378 7.35 and Q374 7.31 ), which stabilizes it more in an 158 inactive state and prevents the inward movement of ECL3 (described above) ( Fig. 2b, d ). 159
Furthermore, the missing N-terminal H1 and the lack of rearrangement in ECL3 would restrict 160 the inward rotation of W304 5.36 , and as a consequence, the translational rotation of TM5 that 161 is important for full activation of GCGR ( Fig. 2d ). Thus, comparison of the NNC1702 and 162 ZP3780-bound GCGR structures provide insights into ligand-dependent conformational 163 changes that might explain the molecular basis of ligand efficacy on the glucagon receptor. 164
One hallmark of GPCR activation is the outward movement of TM6 that is accompanied in 165 Class B GPCRs by the formation of a sharp kink in the middle of the transmembrane domain 166 at the highly conserved PxxG motif 25 . In comparison to the NNC1702-bound receptor structure 167 that shows an outward movement of the extracellular tip of TM6 induced by peptide binding, 168 the ZP3780-bound GCGR:Gs complex reveals partial unwinding of helix 6 above the PxxG 169 (P356 6.47 -L357 6.48 -L358 6.49 -G359 6.50 in GCGR) motif to avoid spatial clashes with both the 170 peptide and the repositioned TM7 ( Fig. 3a the PxxG motif to shift inwards towards TMs 3 and 7 ( Fig. 3a, b ). Substitution of F322 5.54 to 177 alanine results in decreased potency of glucagon (800-fold), showing that the clash of the PxxG 178 motif with TM5 is important for receptor activation (Fig. 3c ). Furthermore, a slight rotation of 179 TM7 away from TM6, caused by the ligand-induced changes described above, helps to 180 accommodate the displaced PxxG motif in the active state of the receptor by releasing the steric 181 hindrance between the newly positioned P356 6.47 and L395 7.52 in TM7 (Fig. 3b ). Another 182 obstacle for kink formation is found in TM3, where the side chain of L242 3.47 would prevent 183 inward movement of the PxxG motif. The observed upward shift of TM3 leads to the removal 184 of this restriction by shifting the leucine side chain away from the PxxG motif ( Fig. 3b ). 185
Individual replacement of the two leucines (L242 3.47 and L395 7.52 ) in TMs 3 and 7 to the smaller 186 alanine side chain leads to a nearly 20-fold decrease in potency and a significant decrease in 187 the maximal glucagon response (Fig. 3c , Suppl. Table 6 ). This highlights the importance of the 188 conformational rearrangements necessary for the inward rotation of the PxxG motif upon 189 receptor activation. The discussed repositioning of the PxxG motif is further stabilized by H-190 bonds with TM5 (G359 6.50 -N318 5.50 ) and TM7 (P356 6.47 -Q392 7.49 ) (Fig. 3b ). 'kink' formation at the conserved PxxG motif (P356 6.47 -L357 6.48 -L358 6.49 -G359 6.50 ). The 195 ZP3780-bound GCGR:Gs complex (cyan) is overlaid with that of the NNC1702-bound GCGR 196
(orange) to highlight structural changes that results in the TM6 outward movement in the 197 GCGR:Gs complex structure. b, Reorientation of residues in TMs 3, 5, and 7 around the PxxG 198 motif that facilitate kink formation in TM6. c, Alanine substitution of residues around the PxxG 199 motif significantly reduce GCGR-mediated cAMP signaling. All mutants were expressed to 200 similar levels as the WT receptor. For c, data represent mean ± s.e.m. from at least three 201 independent experiments, performed in triplicates. 202 203
Below the PxxG motif, the 90° rotation of P356 6.47 perpetuates towards the N-terminus 204 of TM6 that moves away from TM5 maintaining the 90° rotation and is displaced from the 205 receptor core by 18Å to engage the G protein ( Fig. 1b, Fig. 4a ). The conformational alterations 206
in the transmembrane bundle of the receptor open up an intracellular cavity that allows 207 engagement of the heterotrimeric G protein, Gs. The overall structure of the ZP3780-GCGR:Gs 208 complex displays high similarity in the receptor-G protein interactions compared to other 209 reported structures of Class B GPCRs-Gs complexes (GLP-1, Calcitonin, CGRP, PTH), 210 suggesting a common mechanism for G protein engagement and activation (Suppl. Fig. 7 ) 13-211 16, 26, 27 . In the nucleotide-free GCGR:Gs complex, the position of the a5 helix of the G protein 212 requires outward movement of TMs 5 and 6 due to steric hindrance (Fig. 4b ). However, 213
superimposition of the inactive GDP-bound Gs heterotrimer 28 onto the nucleotide-free Gs in 214 the complex suggests that the bent a5 helix of the GDP-bound G protein (a5 GDP ) together with 215 the known inherent flexibility of its very C-terminal end 29,30 , might allow the initial 216 engagement of the GDP-bound G protein without outward displacement of TM6 (Fig. 4b) . In 217 this orientation of a5 GDP , TM5 would need to relocate in order to prevent clashes, but would 218 still allow the establishment of the polar interactions between a5 (e.g. R385) and TM5 as seen 219
in the nucleotide-free state (Fig. 4) . These interactions might facilitate the straightening of a5 220 upon nucleotide release accompanied by outward movement of the intracellular tip of TM6 221
leading to the sharp kink as seen in GCGR and other Class B GPCR complexes. As a result, 222
a5 inserts more deeply into the receptor core to form extensive hydrophilic interactions with 223 residues in TMs 5 and 6 and helix 8 (H8) and hydrophobic contacts with TM3 ( Fig. 4c ). 224
Additional stabilization of the outward conformation of TM6 is provided by rearrangements in 225 the highly conserved HETx motif just below the kink region that has been shown to be 226 important for receptor activation (Suppl. Fig. 8 ) 25, 31 . Removal of the hydroxyl of Y400 7.57 in 227
the HETx motif leads to a 40 percent decrease in maximal cAMP signaling by glucagon as 228 compared to the wild type (Suppl. Fig. 8b ), suggesting the critical role of this polar network 229 for receptor activation. 230
Another important interface between the receptor and the G protein, that has been 231 shown to be important for G protein-signaling of GCGR, is mediated by ICL2 and 3 32 . While 232 ICL3 interacts with residues in the a4/b6 region of the Ras-like domain, ICL2 points into a 233 mostly hydrophobic pocket lined by residues in the aN/b1 hinge and a5 of Gas (Suppl. Fig.  234 9a,b). Furthermore, two arginine residues (R413 8.56 and R417 8.60 ) in H8 are shown to form H-235 bonds with backbone atoms of residues A309 and H311 in the WD7 blade of Gb subunit 236 (Suppl. Fig. 9c ). This H8-Gb interaction seems to be more conserved among Class B 237 receptor:G protein complexes and has been shown to mediate the efficiency of G protein-238 dependent activation of the adenylyl cyclase 14 . 239 240
Conclusions 241
To gain insights into the mechanism of ligand-induced activation of GCGR we designed a 242 glucagon analogue with better aqueous solubility, ZP3780, and determined the structure of a 243 GCGR:Gs signaling complex. The peptide residues H1 and D9, have been shown to be 244 indispensable for ligand potency and efficacy 11,21 . This study provides a structural rationale to 245 explain the wealth of existing structure-activity relationship data for glucagon peptides that has 246 accumulated since the discovery of glucagon by Kimball and Murlin almost 100 years ago 33 . 247
This study will allow the exploration of new avenues for the development of innovative 248 therapeutics to modulate GCGR signaling and its impact on the pathophysiology of diabetes. 249 250 Membranes containing the human GCGR (hGCGR) were prepared as described 34 from a 289 HEK293 cell line stably over-expressing the hGCGR. In brief, for generation of the over-290 expressing cell line, cDNA encoding the hGCGR (P47871) was amplified by PCR using 291 primers encoding terminal restriction sites for subcloning. The 5'-end primer additionally 292 contained a near Kozak consensus sequence. The fidelity of the DNA encoding the hGCGR 293 was confirmed by DNA sequencing. The PCR product encoding the hGCGR was subcloned 294 into a mammalian expression vector containing a neomycin (G418) resistance marker. The 295 mammalian expression construct was transfected into HEK293 cells by a standard liposome 296 transfection method. 48 hours post-transfection, cells were seeded for limited dilution cloning 297 and selected with 0.5 mg/ml G418 in the culture medium. After 2 weeks, surviving colonies of 298 hGCGR-expressing cells were picked, propagated and tested for cAMP accumulation. One 299 hGCGR-expressing clone was selected and used for membrane preparation. 300
For the competition binding experiments 0.06 nM [ 125 I]-glucagon (PerkinElmer, NEX207) was 301 added together with 10 µg hGCGR containing membranes, 0.5 mg SPA-beads (PerkinElmer, 302 RPNQ0001) and varying concentrations of native glucagon or ZP3780. After sharing at 600 303 rpm for 2 h at room temperature the plate transferred to a MicroBeta2 scintillation counter 304 (PerkinElmer) left for 4 h to allow the SPA-beads to settle before quantifying 125 I radioactivity. 305
To determine the respective Ki-values, data were fitted by nonlinear regression to a one-site 306 competition model using GraphPad Prism. 307 308
Functional cAMP accumulation assay 309
The in vitro potencies and efficacies of glucagon and ZP3780 were assessed in a cAMP 310 accumulation assay using HEK293 cells that were transiently transfected with the hGCGR. In 311 brief, HEK293 cells were brought into suspension (0.25x10 6 cells/mL) by trypsination. For 312 transfection of 1 mL of cells in suspension, a total DNA amount of 1 µg, consisting of 0.2 µg 313 hGCGR (accession no P47871) expression vector DNA and 0.8 µg pcDNA3.1(zeo), in 25 µl 314
OptiMEM was mixed with 3 µl FuGene6 in 57 µL OptiMEM and incubated for 20 min. 315
Hereafter the 85 µL DNA/FuGene6 mix was added to 1 mL cell suspension, mixed and seeded 316 in a clear poly-D-lysine coated 96-well in a volume of 100 µL/well (final cell density of 2.5 317 x10 5 cells/well). The amounts were scaled up to the number of data points needed to generate 318 concentration response curves for glucagon and ZP3780. Twenty-four hours after transfection 319 the assay was performed by washing wells once in 100 µL HBSS buffer (HBSS Gibco 14025, 320 20 mM HEPES pH 7.5, 1 mM CaCl2, 1 mM MgCl2 and 0.1% BSA). After the wash, 100 321 µL/well of HBSS buffer supplemented with IBMX (100 µM final concentration) were added, 322 quickly followed by addition of 50 µL of HBSS buffer containing compound dilutions of 323 glucagon and ZP3780. After incubation at 37°C for 15 min, the reactions were stopped by 324 addition of 160 µL lysis buffer. The accumulated cAMP levels were quantified using the 325
CisBIO cAMP dymanic HTRF kit (Cisbio, 62AM4PEC) according to the manufacturer's 326 instructions and measured on an EnVision plate reader (PerkinElmer). Data were fitted by non-327 linear regression using GraphPad Prism. 328 329
Functional testing of the hGCGR mutations was, in general, conducted as described above. The 330 constructs used for the mutational studies all contained a N-terminal FLAG-tag preceded by a 331
HA-signal peptide and were inserted into the pcDNA3.1(neo) expression vector. The following 332
DNA amounts were transfected to ensure similar surface expression to WT hGCGR: WT 333
GCGR was transfected with 0.2 µg/mL cell suspension, Q232A and D385A GCGR with 0.05 334 µg DNA/mL cell suspension, and finally L242A, F322A, D370A, R378A, L395A, and Y400F 335 GCGR were transfected with 0.035 µg/mL cell suspension. Again, in all cases, the total DNA 336 amount was adjusted to 1 µg/mL cell suspension by addition of pcDNA3.1(zeo Expression and purification of heterotrimeric Gs 377
Heterotrimeric Gs was expressed and purified as previously described 35 . Briefly, heterotrimeric 378
Gs was expressed in High Five TM (Trichuplusia ni) insect cells using baculoviruses generated 379 by the BestBac method (Expression Systems). Two separate baculoviruses were used, one 380 encoding the human Gαs short splice variant and the other encoding both the Gβ1 and Gγ2 381 subunits, with an histidine tag and HRV 3C protease site inserted at the amino terminus of the 382 b-subunit. High Five TM cells were infected with the baculoviruses followed by an incubation 383 of 48 h at 27 °C. Cells were harvested by centrifugation and lysed in a buffer comprised of 10 384 mM Tris, pH 7.5, 100 μM magnesium chloride (MgCl2), 5 mM β-mercaptoethanol (βME), 50 385 μM GDP and protease inhibitors. The membrane fraction was collected by centrifugation and 386 solubilized with a buffer comprised of 20 mM HEPES, pH 7.5, 100 mM sodium chloride 387 (NaCl), 1% sodium cholate, 0.05% DDM, 5 mM MgCl2, 5 mM βME, 5 mM imidazole, 50 μM 388 GDP and protease inhibitors. The solubilization reaction was incubated for 45 min at 4 °C after 389 homogenization with a Dounce homogenizer. After centrifugation, the soluble fraction was 390 loaded onto Ni-chelated sepharose followed by a gradual detergent exchange into 0.1 % DDM. 391
The protein was eluted in buffer supplemented with 200 mM imidazole and dialyzed overnight 392 in 20 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% DDM, 1 mM MgCl2, 5 mM βME and 50 μM 393 GDP together with HRV 3C protease to cleave off the amino-terminal 6xHis tag. The cleaved 394 6xHis tag, uncleaved fractions and 3C protease were removed by Ni-chelated sepharose and 395 the G protein was dephosphorylated by lambda protein phosphatase (NEB), calf intestinal 396 phosphatase (NEB), and antarctic phosphatase (NEB). Lipidated Gs heterotrimer was isolated 397 using a MonoQ 10/100 GL column (GE Healthcare). After binding of the protein to the column 398 in buffer A (20 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM MgCl2, 0.02% DDM, 100 μM TCEP 399 and 20 μM GDP), the column was washed with buffer A and the G protein heterotrimer was 400 eluted with a linear gradient of 0-30% buffer B (buffer A with 1 M NaCl). The main peak 401 containing isoprenylated G protein heterotrimer was collected and the protein was dialyzed 402 into 20 mM HEPES, pH 7.5, 100 mM NaCl, 0.02% DDM, 100 μM TCEP and 50 μM GDP. 403
After concentrating the protein to 250 μM, 20% glycerol was added and the protein was flash 404 frozen in liquid nitrogen and stored at -80 °C until use. 405 406
Purification of Nb35 407
Nb35 was expressed in E. coli BL21 cells. After lysis, it was purified on a nickel affinity 408 chromatography and finally subjected to size exclusion chromatography on a Superdex 200 409
